Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DESFERAL vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Deferoxamine is an iron-chelating agent that binds ferric iron forming ferrioxamine, a stable complex that is excreted renally, reducing iron accumulation in tissues.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Acute iron intoxication,Chronic iron overload due to transfusion-dependent anemias (e.g., thalassemia major),Chronic iron overload due to hereditary hemochromatosis with contraindications to phlebotomy,Chelation therapy in patients with secondary iron overload from myelodysplastic syndromes or sickle cell disease (off-label)
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Acute iron poisoning: 1 g IM, then 0.5 g IM every 4-12 hours; max 6 g/day. Chronic iron overload: 0.5-1 g IM daily; also IV/SC 20-40 mg/kg/day over 8-24 hours.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Terminal elimination half-life: 6-12 hours (prolonged in iron overload, up to 20-30 hours with large doses; clinical context: supports subcutaneous infusion over 8-12 hours for chronic chelation).
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Deferoxamine is metabolized primarily in the liver via oxidative deamination to two major metabolites: an acid-degradation product and a neutral compound. The exact enzymes are not well-defined but likely involve hepatic oxidases.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Renal: approximately 40-60% of absorbed dose excreted in urine as unchanged drug and iron complex; biliary/fecal: minor route, <5%.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
~10-20% bound to plasma proteins; primarily albumin and transferrin (minimal due to low affinity).
10-25% bound to albumin at therapeutic concentrations.
Dry weight: 1.5-2.0 L/kg (indicates extensive distribution into extracellular fluid and tissues; increased in iron overload due to iron stores).
0.8-1.0 L/kg. Indicates distribution into total body water.
Subcutaneous: ~80-90% (injectable only; oral bioavailability negligible, <5%).
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
GFR >60 m L/min: no adjustment; GFR 10-60: reduce dose by 50%; GFR <10: avoid use or use with extreme caution.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Acute poisoning: 15 mg/kg/h IV initially, max 6 g/24h; acute chronic overload: 20-40 mg/kg/day SC/IV over 8-24h.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Start at lower end of dosing range due to potential renal impairment; monitor renal function and iron levels.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Hypersensitivity reactions including anaphylaxis, urticaria, and angioedema,Ocular toxicity (cataracts, decreased visual acuity, retinal damage) with high doses or prolonged therapy,Auditory toxicity (tinnitus, sensorineural hearing loss) especially at high doses,Renal impairment may reduce drug clearance; monitor renal function,Growth retardation in children with long-term use,Increased risk of infections, particularly Yersinia enterocolitica and Mucorales fungi,Severe neurotoxicity including seizures, coma, and encephalopathy, especially with rapid intravenous administration,Acute respiratory distress syndrome (ARDS) reported with rapid IV infusion
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Severe renal disease or anuria (as drug is excreted renally),Hypersensitivity to deferoxamine or any component of the formulation,Primary hemochromatosis with mild iron overload (prefer phlebotomy)
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Avoid high-iron foods (e.g., red meat, liver, fortified cereals) during therapy. Do not take with vitamin C supplements as they may increase iron absorption and toxicity. No significant food interaction except iron-containing foods/supplements.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
FDA Category C. First trimester: Animal studies show fetal abnormalities, but no adequate human studies. Second/Third trimesters: Avoid unless essential; deferoxamine crosses placenta and may cause fetal skeletal anomalies, anemia, and growth restriction at high doses.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Excreted into breast milk in low levels; M/P ratio unknown. Use with caution, especially in infants with iron overload; consider risk of maternal iron deficiency. Monitor infant for gastrointestinal effects.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No standard dose adjustment; lower doses may be required due to increased plasma volume and renal clearance. Monitor iron levels closely; avoid high doses to minimize fetal toxicity.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
Administer IM or IV, but avoid rapid IV infusion to prevent hypotension. Monitor urine color for reddish hue indicating iron excretion. For acute iron poisoning, check serum iron and total iron-binding capacity (TIBC); chelation is indicated if serum iron exceeds TIBC or >350 mcg/d L. Use test dose (50 mg/kg) if uncertain of iron overload. Avoid in severe renal failure unless dialysis is available due to desferrioxamine-iron complex excretion. Can cause Yersinia enterocolitica infection; discontinue if fever or diarrhea develops.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Take this medication exactly as prescribed; it is given by injection under the skin, into a muscle, or into a vein.,Your urine may turn a reddish-brown color during treatment; this is normal and indicates iron excretion.,Report any signs of infection such as fever, sore throat, or diarrhea immediately.,Avoid alcohol and large amounts of vitamin C unless approved by your doctor, as they can affect iron removal.,Stay hydrated; drink plenty of fluids unless instructed otherwise.,Do not take any iron supplements or multivitamins containing iron without consulting your healthcare provider.,If you miss a dose, contact your doctor for instructions; do not double the dose.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DESFERAL vs OFIRMEV, answered by our medical review team.
DESFERAL is a Iron Chelating Agent that works by Deferoxamine is an iron-chelating agent that binds ferric iron forming ferrioxamine, a stable complex that is excreted renally, reducing iron accumulation in tissues.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DESFERAL and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DESFERAL is: Acute iron poisoning: 1 g IM, then 0.5 g IM every 4-12 hours; max 6 g/day. Chronic iron overload: 0.5-1 g IM daily; also IV/SC 20-40 mg/kg/day over 8-24 hours.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DESFERAL and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DESFERAL is classified as Category C. FDA Category C. First trimester: Animal studies show fetal abnormalities, but no adequate human studies. Second/Third trimesters: Avoid unless essential; deferoxamine crosses place. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.